Sign in Subscribe

Alex Chompff

China Issues Expert Consensus on Early-Onset CRC Management

Skip to content The CRC Digest China Issues Expert Consensus on Early-Onset CRC Management New guidelines address the unique needs of younger patients, including fertility preservation, sexual function, and long-term quality of life considerations. (Zhonghua Wei Chang Wai Ke Za Zhi) This content is informational only and does not constitute

PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer Preclinical research using single-cell RNA sequencing found that PLOD2, often overexpressed in colorectal cancer, has been implicated in promoting tumor growth and epithelial-mesenchymal transition. Functional assays in CRC cell lines with PLOD2 knockdown showed

Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy A multicenter study of 452 colorectal cancer patients who received neoadjuvant immunotherapy analyzed the incidence of immune-related adverse events and perioperative outcomes following curative surgery. (Zhonghua Wei Chang Wai Ke Za Zhi)

Study Assesses New FIT Buffer for Hemoglobin Preservation

Skip to content The CRC Digest ▪ SCREENING Study Assesses New FIT Buffer for Hemoglobin Preservation A study assessed the faecal hemoglobin preservation capacity of a new faecal immunochemical test buffer formulation (SOC4) at varying temperatures and storage times. Fresh faecal samples were collected using buffers containing either the standard (SOC3)

Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III Trial Compares Total Neoadjuvant Therapy Approaches in High-Risk Rectal Cancer A multicenter, randomized phase III trial evaluated total neoadjuvant therapy with long-course radiotherapy versus chemoradiotherapy in patients with high-risk locally advanced rectal cancer. (Journal of Clinical Oncology) This content is

DHODH Identified as Metabolic Vulnerability in PIK3CA-Mutant Colorectal Cancer

Skip to content The CRC Digest DHODH Identified as Metabolic Vulnerability in PIK3CA-Mutant Colorectal Cancer Preclinical research identifies dihydroorotate dehydrogenase (DHODH) as a selective metabolic dependency in PIK3CA-mutant CRC; DHODH inhibition reduces cancer cell self-renewal and tumor initiation by disrupting PI3K-AKT signaling. (Cell Reports) This content is informational only and

Validated Scale Helps Measure Treatment-Induced Neuropathy in Chinese Patients

Skip to content The CRC Digest Validated Scale Helps Measure Treatment-Induced Neuropathy in Chinese Patients A prospective study of 254 colorectal cancer patients receiving oxaliplatin validated the Treatment-induced Neuropathy Assessment Scale (TNAS) and established cutpoints for numbness, sensory symptoms, and interference with daily activities. (Quality of Life Research) This content

Pediatric Colorectal Cancer in Africa: Multicenter Study Reveals Late Diagnosis

Skip to content The CRC Digest Pediatric Colorectal Cancer in Africa: Multicenter Study Reveals Late Diagnosis A 14-country African study of 108 children and adolescents (mean age 14.9 years) diagnosed with CRC found a mean symptom-to-diagnosis duration of 90 days, with most presenting with abdominal discomfort and bowel habit

Childhood Cancer Survivors Underutilize Colorectal Cancer Screening

Skip to content The CRC Digest ▪ SCREENING Childhood Cancer Survivors Underutilize Colorectal Cancer Screening A French national study found that childhood cancer survivors participated in fecal immunochemical testing at rates of 20.0% to 23.2% across three screening periods—significantly lower than the general population—despite their elevated CRC

KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy

Skip to content The CRC Digest ◇ RESEARCH KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring